Archive for June, 2008
June 17th, 2008. Mapping the Risk of Mesothelioma due to Neighborhood Asbestos Exposure
Conclusions: Neighborhood exposure to asbestos can pose a serious risk to residents across a wide area.
June 15th, 2008. Prognostic role of osteopontin expression in malignant pleural mesothelioma
0001), and overall survival analysis showed that low osteopontin expression was associated with longer survival; multivariate analysis confirmed the value of osteopontin expression as an independent prognostic factor (P < . 0001).
June 15th, 2008. SV40 large T antigen-specific human T cell memory responses
Peptide-stimulated T cells also killed SV40 Tag-transfected target cells. This article demonstrates the presence, and provides a detailed analysis, of SV40-specific T cell memory in man.
June 13th, 2008. Pericardial effusion due to metastatic prostate cancer: a case report
He died suddenly because of ventricular tachycardia. At autopsy, the major finding was poorly differentiated adenocarcinoma of the prostate with metastases to the mediastinum.
June 11th, 2008. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
Posted in Carboplatin, Causation, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Immunohistochemistry or IHC, Occupational Asbestos Exposure, Pemetrexed (Alimta), PET Scan, Pleural, Treatment, Type of Assessment: | No Comments »
June 11th, 2008. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.
June 11th, 2008. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
Conclusions: The combination of erlotinib and bevacizumab was tolerated reasonably well, but there was no evidence of radiographic response. This study demonstrates the feasibility of conducting trials in mesothelioma patients who have failed first-line therapy. More therapeutic studies with effective agents are needed for these patients.
June 6th, 2008. Excess of Mesotheliomas after Exposure to Chrysotile in Balangero, Italy
Conclusions: The cluster of 14 mesothelioma cases among workers who were active in the mine and 13 among other people exposed to Balangero chrysotile adds further evidence to the carcinogenicity of tremolite-free chrysotile.
June 6th, 2008. Uroplakin is not a Reliable Immunohistochemical Marker for Malignant Mesothelioma of the Pleura
Conclusions: At an antibody dilution for which positive and negative control tissues stain appropriately, PMM does not stain for URO. At higher antibody concentrations, PMM exhibits nonspecific cytoplasmic staining. We assert that URO is not a useful immunohistochemical marker for the detection of PMM. Further studies addressing whether URO is overexpressed at the mRNA level in PMM are warranted.
June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
Posted in Causation, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Intraperitoneal Chemotherapy, melphalan, Occupational Asbestos Exposure, Oxaliplatin (Eloxatin), paclitaxel, PET Scan, Pleural, Pleural Catheters, Proton Beam Therapy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment: | No Comments »
June 6th, 2008. Diagnostic usefulness and challenges in the diagnosis of mesothelioma by endoscopic ultrasound guided fine needle aspiration
Real time endoscopic ultrasound (EUS) combined with FNA has been shown to be a very sensitive technique to obtain samples from different organ sites, including mediastinal lesions. The use of EUS-FNA for the diagnosis of mesothelioma, reinforces the role of a cytopathologist as a cohesive team player along with a radiologist and a clinician during on-site assessment for the proper triage of additional specimens for ancillary studies leading to a better patient management.
June 6th, 2008. Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: A case report
The identification of a collagenous ball within these clusters is a useful cytologic finding for the diagnosis of WDPM. WDPM should be suspected when numerous collagenous balls are present by effusion cytology and isolated cells are not.
June 5th, 2008. Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine
Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.
Posted in Case Study, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Epithelioid, Full Archive, Gemcitabine (Gemzar), Pleural, Pleural Biopsy, Staging, Symptoms & Symptom Management, thoracoscopy, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine | No Comments »
June 4th, 2008. An autopsy case of diffuse pleural thickening presented respiratory impairment and benign asbestos pleurisy
The autopsy disclosed asbestos-related lung diseases. We suspected that diffuse pleural thickening could be a major cause of fatal respiratory impairment in this case.
Posted in Case Study, Causation, CT or CAT scan, Diagnosis & Differentiation, Full Archive, Occupational Asbestos Exposure, Pleural Biopsy, Pleural Effusion, Symptoms & Symptom Management, thoracoscopy, Type of Assessment: | No Comments »
June 4th, 2008. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies
Most clinical studies have been conducted in patients with malignant mesothelioma, and a confirmatory Phase IIIb trial is currently underway for the treatment of this disease. Owing to its selective destruction of malignant cells and favorable toxicology profile, ranpirnase is a promising antitumor agent with ideal attributes that are generally lacking in conventional cytotoxic drugs.
June 4th, 2008. Pulmonary Paragonimiasis with Coincidental Malignant Mesothelioma
Here, we report a very rare case of malignant mesothelioma with a concomitant infection of parasitic lung fluke. Keywords: paragonimiasis, malignant mesothelioma, eosinophilia.
June 4th, 2008. Malignant mesothelioma 2008
Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success. Finally there are several attempts at immunomodulating and targeted treatments, which are in phase I/II trials.
Posted in Causation, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Full Archive, General, Immune-based Therapies, New & Novel, Occupational Asbestos Exposure, Photodynamic Therapy (PDT), Radiation, Serum Marker/Blood Test, Survival, SV40, Treatment, Type of Assessment: | No Comments »
June 4th, 2008. The relationship between simian virus 40 and mesothelioma
Epidemiological data possibly linking simian virus 40 and malignant mesothelioma is lacking owing to unattainable identification of infected from noninfected cohorts. Summary: Available evidence appears sufficient to link simian virus 40 either alone or in conjunction with asbestos in causing malignant mesotheliomas; however, it is still insufficient to speculate about the contribution of simian virus 40 to the overall incidence of malignant mesotheliomas.
June 4th, 2008. Mesothelioma due to environmental exposure to erionite in Turkey
It has also been confirmed that a genetic predisposition to erionite carcinogenesis is the cause of the mesothelioma epidemic in Cappadocia. Summary: The data obtained recently on the epidemiology, etiology, and pathogenesis of the mesothelioma due to erionite exposure in Turkey are described.
June 4th, 2008. Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues
thoracoscopic) pleural puncture sites and reserving treatments to symptomatic deposits may be more appropriate. This strategy would optimize patient care and minimize hospital visits, but allow prompt instigation of treatment if symptoms develop.
|
|  |
